RemeGen Co

RemeGen Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co (688331.SS) as of Oct 26, 2026 is 880.75. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -44.50 — a change of -2,079.01% (higher).

EV/OCF

880.75

YoY

-2,079.01%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co is 2025 880.75 . EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co was 2024 -44.50 . It decreases by -2,079.01% higher compared to the previous year.

The RemeGen Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-400.77 CNY
Jan 1, 2019
-180.62 CNY
Jan 1, 2020
-72.54 CNY
Jan 1, 2021
185.10 CNY
Jan 1, 2022
-38.42 CNY
Jan 1, 2023
-33.96 CNY
Jan 1, 2024
-44.50 CNY
Jan 1, 2025
880.75 CNY
The RemeGen Co EV/OCF history
YEAREV/OCFYoY
880.75-2,079.01%
-44.50+31.05%
-33.96-11.60%
-38.42-120.76%
185.10-355.17%
-72.54-59.84%
-180.62-54.93%
-400.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co is 880.75 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co changed from -44.50 to 880.75, representing a -2,079.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — RemeGen Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — RemeGen Co